Chemotherapy recipients were also those patients characterized by a statistically significantly lower median CRP and NLR, leading us to postulate whether the protective effect of chemotherapy on COVID-19 sequelae might be related to a therapy-dependent modulation of the proinflammatory response. This evidence concerns the gene CRP and COVID-19.